Agios Pharmaceuticals

Agios Pharmaceuticals Inc. is a public American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.^[3] The company was founded in 2008 (or 2007)^[4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.^[2][5] The company tendered an initial public offering in July 2013.^{[6]: Table 1}

Agios Pharmaceutical Inc.

Type	Public
Traded as	Nasdaq: AGIO Russell 1000 Component
Industry	Pharmaceuticals
Founded	2008 (2008)
Headquarters	Cambridge, Massachusetts , United States
Key people	Brian Goff (CEO)
Revenue	$118 Million(2019)^[1]
Number of employees	536
Website	agios.com
Footnotes / references Foundation^[2]

History

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.^[4]

In May 2016, the company announced it would launch partnership with Celgene,^[7] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.^[8]

In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug, Enasidenib^[9]

In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or R/R AML with an IDH1 mutation.^[10]

In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.^[11]

In April 2022, FDA approved PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for hemolytic anemia in adults with Pyruvate Kinase Deficiency.^[12]

Corporate governance

As of August 2022^[update], Agios' CEO is Brian Goff.^[13]

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.^[4][6]

References

1. "Agios Reports Fourth Quarter and Full Year 2019 Financial Results – Agios Pharmaceuticals, Inc".
2. Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
3. "About Us".
4. Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times. 
5. "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
6. Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71. 
7. "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN. 17 May 2016.
8. Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
9. "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
10. Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.
11. "Agios Announces Pricing of $256 Million Public Offering of Common Stock". www.nasdaq.com. Retrieved 2020-03-12.
12. "Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency". Agios. Cambridge, MA. 17 February 2022. Retrieved 24 April 2023.
13. "Agios Appoints Brian Goff as Chief Executive Officer".